From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: In detail why Novacyt and Avacta are both shorts

By Tom Winnifrith | Sunday 4 February 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I explain why Novacyt (NCYT) is a zero and Avacta (AVCT) is not a zero but at two levels is a short. I also discuss how companies pretend that the cost of an acquisition is less than its true cost ref Novacyt and also Skinbiotherapeutics (SBTX). And I have updates on Sharestock 2024, more details and ticket booking can be found HERE. 
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Wednesday »

Tom

Are you coming to Sharestock on September 7?

 

VANL

Van Elle Holdings – a Buy?

Thursday »

CCT

Character Group – a Buy?

 

ING

Ingenta – now a Buy again?

Time left: 00:24:07